Heartbeat Clinic in Dallas Acquires Blood Volume Analyzer; Daxor Corporation Announces 250,000 Share Buyback

Marketwired

NEW YORK, NY--(Marketwire - Mar 21, 2013) - Daxor Corporation (NYSE MKT: DXR)

The Heartbeat Clinic is a specialized cardiology practice providing state of the art cardiac rhythm management options. Dr. Amer Suleman, a Cardiologist, is also the director of the Heartbeat Clinic, and an adjunct professor at UT Dallas and an editor of Cardiology on WebMD. Currently, the Heartbeat Clinic which is based in Medical City serves approximately 2000 patients and continues to grow. Dr. Suleman was quoted as saying, "We are very pleased to begin to provide this valuable test to our patient population in the Dallas-Fort Worth area. We believe the valuable information which a blood volume analysis test provides along with titrating therapies can truly aid in preventing hospital admissions."

The Heartbeat Clinic specializes in helping patients manage and deal with blackout spells, palpitations, lightheadedness, irregular heartbeat and related disorders of the autonomic nervous system. They also offer complete cardiology services and point of care testing for cholesterol, liver function, and thyroid function. Through echocardiograms, contrast echocardiograms, tilt table tests, stress tests, autonomic nervous system tests, and numerous research protocols that support research. The Heartbeat Clinic is proud to offer the most extensive monitoring service in the Dallas-Fort Worth metroplex.

Daxor Corporation manufactures and markets the BVA-100 Blood Volume Analyzer, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. Blood volume derangements are an integral part of the decompensation which afflicts congestive heart failure patients. Previous published studies have demonstrated that experienced cardiologists are only correct 51% of the time in estimating whether the patients have an expanded normal, or decreased blood volume. Patients whose medical treatment results in a restoration of a blood volume to normal have a much better prognosis than patients whose treatment does not accomplish this goal. Direct measurement of blood volume enables physicians to precisely target a patient's treatment goals. 

The Board of Directors of Daxor Corporation held a meeting on March 20, 2013 and approved the renewal of the 250,000 share buyback program of Daxor stock. In 2012 Daxor repurchased 69,000 of its shares on the open market. Due to various regulatory limitations the company was not able to buy back all the shares that were authorized in 2012. 

For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com.

Contact:
Daxor Contact Information:
Richard Dunn
Director of Operations
212-330-8502
rdunn@daxor.com
or
Diane Meegan
Investor Relations
212-330-8512
dmeegan@daxor.com
View Comments (0)